Pasithea Therapeutics CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Pasithea Therapeutics Executive Chairman Lawrence Steinman Reports Reduced Stake Below 5%
Lawrence Steinman, Executive Chairman of Pasithea Therapeutics Corp., has filed an amended Schedule 13D indicating his beneficial ownership has fallen below the 5% threshold as of March 1, 2025.